Dante Labs Receives Italian Government Grant to Pilot Groundbreaking CE-IVD, Citizen Test Based on Clinical Whole Genome Sequencing for a G7 Country, Ushering in a New Era in Clinical Genomics

Dante Laboratories

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Dante Laboratoriesa world leader in genomics and precision medicine, is pleased to announce that the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully CE-IVD and clinically-based whole genome sequencing (WGS) assay approved for Italian citizens to be named the Dante Citizen Test.

The goal of the project is to introduce clinical whole genome sequencing with clinical reports into the standard medical care of hospitals and the country’s health system and is the first step to introduce whole genome sequencing into the health system. national of a European country and of the G7. The test will rely on Dante’s proprietary Extensa software for reporting, interpretation and analysis of whole genome and medical data.

“Clinical whole genome sequencing will finally become a standard solution in public healthcare systems, not as a luxury for the few but as a right for every citizen, thanks to the Dante Citizen Test,” said Andrea Riposati, CEO of Dante Labs. “Effective use of whole genome sequencing in standard clinical care requires proficiency in sequencing, interpreting and integrating medical information, at scale. That’s what we’ve done at Dante. Now , through partnerships with forward-thinking governments like Italy, we can impact millions of patients around the world.

The groundbreaking project will be overseen by Dante’s newly appointed European Medical Genomics Committee, which is comprised of global national and multinational genomics leaders, including geneticists, molecular biochemists and clinical experts in pharmacogenomics, nutrigenomics and oncogenomics, diseases rare prenatal, neonatal and pediatric. .

About Dante Laboratories

Dante Labs is a global genomics information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The company uses its platform to deliver better patient outcomes, from diagnosis to therapy, with assets including one of the largest private genomic databases with research consent, proprietary software designed to unleash the power of large-scale genomic data and proprietary processes that enable an industrial approach to genomics. sequencing.


Laura D’Angelo
Vice President of Investor Relations
[email protected]
+39 0862 191 0671